ENvue Medical, Inc.
FEEDHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at-home administration. At a $2.2M market cap, ENvue Medical, Inc. ranks as a micro-cap company within healthcare. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.
Market Cap
$2.2M
Beta
1.56
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-3.67
EPS (Fwd)
—
ROE
-59.5%
ROA
-20.2%
Cash
$2.2M
Total Debt
$1.2M
Free CF
-$6.8M
52W Change
-96.2%
Annual Financials
Cash vs Debt
Where FEED stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, FEED finished 74.30% below its 150-day moving average ($1.79) and 82.71% below its 200-day moving average ($2.66). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FEED overbought or oversold?
At the July 15, 2026 close, FEED's RSI(14) was 29.0, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $2.2M in cash comfortably exceeding the $1.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$6.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -59.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $752K (2022) to $2.6M (2025), reflecting a 239% increase over the period.
A beta of 1.56 means FEED is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence ENvue Medical, Inc.'s trajectory.